Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository (original) (raw)
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository
Ignasi Rodriguez Pinto, Maria Efthymiou
Arthritis Care & Research, 2020
View PDFchevron_right
The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody Positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository
Maria Efthymiou
Arthritis care & research, 2018
View PDFchevron_right
Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes
Desmond Y H Yap
Lupus, 2019
View PDFchevron_right
Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice
Sylvana Sackey-Sam
Rheumatology Advances in Practice, 2021
View PDFchevron_right
The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository
Guilherme De Jesus
Arthritis Care and Research, 2018
View PDFchevron_right
Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities
D. Roccatello
Journal of Thrombosis and Haemostasis, 2012
View PDFchevron_right
Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?
Alberto Calligaro
Annals of the Rheumatic Diseases, 1994
View PDFchevron_right
Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study
Cristiano Moura
Scientific Reports, 2020
View PDFchevron_right
Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study
Simone Baldovino
Frontiers in Immunology
View PDFchevron_right
Extended antiphospholipid antibodies screening in systemic lupus erythematosus patients
Alina Dima
Romanian Journal Of Internal Medicine, 2015
View PDFchevron_right
The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-β2-glycoprotein I antibodies
Jeannine Kassis
Rheumatology, 2006
View PDFchevron_right
The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-b2-glycoprotein I
Paul Fortin
Rheumatology, 2006
View PDFchevron_right
Real world experience with antiphospholipid antibody tests: how stable are results over time?
Ron Kaplan
Annals of the Rheumatic Diseases, 2005
View PDFchevron_right
A Comparison of Lupus Anticoagulant Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without
Vittorio Pengo, P. Gresele
Arteriosclerosis Thrombosis and Vascular Biology, 2007
View PDFchevron_right
The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti- 2-glycoprotein I antibodies
Susan Solymoss
Rheumatology, 2006
View PDFchevron_right
Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
Marta Tonello
Journal of Thrombosis and Haemostasis, 2013
View PDFchevron_right
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository
Guilherme De Jesus
Arthritis Care and Research, 2022
View PDFchevron_right
Antiphospholipid Antibody Syndrome-Diagnostic Issues of Lupus Anticoagulants
Ankur Ahuja
Journal of Hematology & Thromboembolic Diseases
View PDFchevron_right
Prevalence and Clinical Correlation of Anti-PhospholipidBinding Protein Antibodies in Anticardiolipin-Negative Patients With Systemic Lupus Erythematosus and …
Marilina Tampoia
2009
View PDFchevron_right
Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository
Maria Tektonidou
Journal of Thrombosis and Haemostasis, 2019
View PDFchevron_right
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry
Ángeles Aguirre
Lupus, 2020
View PDFchevron_right
Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus
Selcan Demir
Rheumatology, 2020
View PDFchevron_right
Identification of patients with triple antiphospholipid antibody positivity is platform and method independent
Stanisław Polański
Polskie Archiwum Medycyny Wewnętrznej, 2016
View PDFchevron_right
Specificity and sensitivity of anti-β 2 -glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome
Pantep Angchaisuksiri, Kitti Totemchokchyakarn
Clinical Rheumatology, 2007
View PDFchevron_right
Significance of anti-phospholipid antibodies in patients with lupus nephritis
John Stewart Cameron
Kidney International, 1991
View PDFchevron_right
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
gregorio soler
Lupus, 2020
View PDFchevron_right
Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants
Simone Baldovino
Blood, 2010
View PDFchevron_right
Practical Considerations and Testing Nuances for the Detection of Lupus Anticoagulant: Do Low Phospholipid Screen Results, Assay Type, and Test Ratio Matter?
Parul Bhargava
American Journal of Clinical Pathology, 2021
View PDFchevron_right
IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome
Patrizia Della Valle
Haematologica, 1999
View PDFchevron_right
IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations
Michael Samarkos
Rheumatology (Oxford, England), 2001
View PDFchevron_right